CUVET Successfully Developed the First Stem Cell Transplantation Technology to Treat Pet Diabetes – Yahoo Finance

BANGKOK, Dec. 2, 2022 /PRNewswire/ — For the first time in Thailand, a research team from Chula’s Faculty of Veterinary Science (CUVET) is the first to have successfully developed a method to culture dog pancreatic cells from stem cells and cell transplantation technology. They aim to test the method in the lab and sick animals suffering from diabetes. 
Diabetes affects not only humans but also our pets with as many as 5-10 % of the cases found in cats as well as dogs. Treatment with insulin injections is still not very effective. For this reason, a research team from Chula’s Faculty of Veterinary Science has collaborated with Bio ink Co., Ltd., one of Chula’s spin-off companies, to develop a method for pancreatic cell culture from stem cells and cell transplantation technology for the first time in Thailand.
“Diabetes in humans and pets share some similarities though the knowledge on the treatment is far apart. Using stem cells and advanced forms of technology to treat diabetes in human beings has become a trend, so we try to apply this technology to animal treatment as well,” Assistant Professor Dr. Chenpop Sawangmek, Department of Veterinary Pharmacology Science, Faculty of Veterinary Science, Chulalongkorn University and co-founder of Bio ink Co., Ltd. described the motivation that led to this project. 
“Diabetes is a chronic disease and complications can be fatal to our pets. The inability to control sugar levels can also cause the deterioration of various organs in the body. This is a cause of much suffering for the pets as well as their owners, not to mention the financial burden.”
Stem cell innovation in the treatment of diabetes in animals
According to Assistant Professor Dr. Chenpop, the type of diabetes mostly found in dogs is type 1 diabetes where the body lacks beta-cells to create insulin resulting in insulin deprivation in their bodies. For type 2 diabetes, mostly found in cats, the body still has beta-cells but there is a deficiency in insulin secretion or insulin resistance. Treatment for the two types of diabetes is therefore different.
Dr. Sirirat Nantavisai and Dr. Watchareewan Rodprasert co-founders of Bio Ink Co. Ltd. enumerated that for this research, the Veterinary Stem Cell and Bioengineering Innovation Center (VSCBIC), a research unit of CUVET, and Bio Ink Co, Ltd. focused primarily on the type 1 diabetes in dogs as the currently used insulin injections treatment for dogs is not very effective.
“During the research process, we will create dog’s pancreatic cells which one might call insulin-producing cells (IPCs) derived from canine mesenchymal stem cells (cMSCs) while developing transplantation technology to use in replacing pancreatic cells that have been damaged or destroyed. The cells that have been produced can efficiently create and secrete insulin.”
Dr. Watchareewan further explained that when used along with the double encapsulation transplantation technology, this method produces strong cells and prevents them from damage and deterioration while also preventing rejection from the immune system.
Stem cells and the hope for treating diseases in human beings and animals
At present, the research team has developed canine cell tissue for stem cell extraction and multiplication. It has also been successful in creating the process of inducting cells along with transplantation technology. This platform has been successful and is now ready to be tested for its efficiency and safety in both lab and sick animals. It is estimated that within 3 years it can be used as an actual form of treatment in animals.
“Stem cells can be adapted for use in various ways. If we can successfully develop cells from stem cells, in the future all organs can be directly replaced by cells or tissues. We are studying these options along with creating prosthetic bones to replace damaged bones or accelerate their repair along with producing eye cornea which is a collaborative research project between the faculties of Medicine and Engineering,” said Assistant Dr. Chenpop.
Plans for producing medical products from stem cells
With knowledge in bioengineering and stem cell technology, the Faculty of Veterinary Science VSCBIC research unit and Bio Ink Co. Ltd. now have plans to develop stem cell products like cell therapy and stem-cell-derived products to treat pets soon. One example is the exosome product that can be used for sick pets or administered to damaged organs for rehabilitation and repair. It can also be adapted to treat such diseases as cancer, liver or kidney disease, and diseases stemming from organ deterioration, infections, or illnesses related to the immune system. The products are expected to be tested on lab animals within the year and in no more than two years will be offering them commercially.
For those interested kindly contact https://www.cuvscbic.com/.
For the full release and more images, please visit: https://www.chula.ac.th/en/highlight/92729/
About Chulalongkorn University
Chulalongkorn University sets the standard as a university of innovations for society and is listed in the World’s Top 100 Universities for Academic Reputation, in the Quacquarelli Symonds (QS) World University Rankings 2021.
***********************
If you would like more information about this topic, please contact Miss Thanita Wangvanichapan at (+66) 2218 3280 or email thanita.w@chula.ac.th
***********************
 
SOURCE Chulalongkorn University
Yahoo Finance’s Jared Blikre breaks down how stocks are trading following the November jobs report.
The Labor Department monthly jobs report for November at 8:30 a.m. ET on Friday. Here are the highlights, compared to Wall Street estimates.
And if you’re behind? It’s OK boomer. There’s still some time to catch up.
The Tesla CEO unveiled the production version of the EV-maker’s long awaited Tesla Semi, an all-electric class 8 commercial semi truck.
Dow Jones futures dived 400 points on a strong November jobs report. Tesla fell after delivering its first all-electric semitrailer truck.
AWS continues to push the envelope to vertically integrate, challenging other top software and hardware suppliers.
Buyers are getting squeezed by higher real estate prices and soaring mortgage rates, which could force more out of the market.
Yahoo Finance Live checks out shares of the Blackstone Group after announcing limits to withdrawals from real estate funds.
MarketWatch Picks has highlighted these products and services because we think readers will find them useful; the MarketWatch News staff is not involved in creating this content. “You will want to consider your health, income, expenses, inflation, and other financial goals, as well as whether you have sufficient assets and are confident in your understanding of what retirement entails.”
U.S. stock futures sank Friday morning after the Labor Department's monthly jobs report for November showed payrolls grew by 263,000, higher than estimated, while unemployment held at 3.7%. Bloomberg expected a print of 200,000 for the month.
Weaker demand for lumber has weighed on prices, making it one of the biggest commodity price decliners this year. The outlook isn’t good, either.
We’re getting near an inflection point in the markets, and change is in the air. In the immediate short-term, the Fed is expected to slow down on its rate-hike policy. While another rate hike – seventh for 2022 – is widely predicted for this month, Fed Chair Jerome Powell made it clear yesterday that the Fed will likely raise rates by 50 basis points, rather than 75. Chalk that up to two factors: the slowdown in the rate at which inflation is increasing, per the October numbers, and the risk tha
Profit from folly. Don’t participate in it.
When people think of the players that dominate the Las Vegas Strip, their thoughts generally turn to Caesars Entertainment and MGM Resorts International , which dominate the south and central parts of the Strip. Caesars owns its namesake Caesars Palace, Harrah's, Planet Hollywood, the Cromwell, the Flamingo, Bally's (soon to be Horsehoe), the Linq, and Paris Las Vegas. After that, thoughts turn to other players like Wynn Resorts , the brand new Resorts World International, and the Venetian, which is operated by Apollo Global Management .
The master limited partnership has always had a higher yield, but 7.7% is way above what we've seen before.
2022 has been a disaster for Palantir Technologies' (NYSE: PLTR) stock — it's down 61% this year. Despite solid revenue growth, Palantir is still unprofitable, which is a red flag for many investors in times of macroeconomic uncertainty. With 2023 around the corner, could it be the year investors take notice of Palantir's stock?
Yahoo Finance's Seana Smith highlights which stocks are making moves in after-hours trading on Thursday.
In this article, we discuss the 11 best aggressive stocks to buy now. If you want to read about some more aggressive stocks, go directly to the 5 Best Aggressive Stocks to Buy Now. Aggressive stocks are high-risk, high-reward growth stocks that can provide investors with strong returns. Growth stocks offer a substantially higher growth […]
Question: I have heard it a thousand times: “People make more money with a financial advisor, don’t lock in your losses, stay invested,” etc. So I started with a financial adviser at a national firm in March. It has been a nearly continuous plunge of my savings, with a 13% loss in my portfolio, and yet not one adjustment has happened. If you have a portfolio that’s 50% stocks and 50% bonds, and you’re only down 13%, that means you’ve done fairly well, explains Joe Favorito, certified financial planner at Landmark Wealth Management.
If you keep money in a regular savings account you will generally owe federal income taxes on the interest that is earned. You'll pay taxes at your regular rate the year interest is earned, whether or not you withdraw from … Continue reading → The post How to Avoid Tax on a Savings Account appeared first on SmartAsset Blog.

source